FRIDAY, MARCH 30, 2012
8:00AM – 8:45AM Registration and Continental Breakfast
8:45AM - 9:00AM Welcome and Introduction

SESSION I: PHARMACOGENETICS OF SUBSTANCE ABUSE
Session chair: Alessandro Serretti, MD, PhD

9:00AM - 9:25AM Effects of COMT val158met genotype in African and European American smokers and intravenous nicotine administration
Aryeh Herman, PsyD
Yale University
New Haven, CT, USA

9:25AM - 9:50AM Variation in OPRM1: Moderates the effect of desire to drink on subsequent drinking and its attenuation by Naltrexone treatment
Henry R. Kranzler, MD
University of Pennsylvania
Philadelphia, PA, USA

9:50AM - 10:05AM Break

SESSION II: PHARMACOGENETICS OF MOOD AND ANXIETY DISORDERS
Session chair: James Kennedy, MD

10:05AM - 10:30AM Association study of 50 candidate genes and lithium response in bipolar disorder
John Kelsoe, MD
University of California, San Diego
La Jolla, CA, USA

10:30AM - 10:55AM Impact of genetic variation in CYP enzymes on treatment response in OCD
Eva J. Brandl, MD
Centre for Addiction and Mental Health
Toronto, ON, CA
10:55AM - 11:20AM  Identifying transcriptomic biomarkers for response to escitalopram in the inflammatory cytokine pathway  
Timothy Powell  
King’s College, London  
London, England, UK

11:20AM - 11:45AM  Variation in the serotonin transporter gene (SLC6A4) and serotonin receptor 2A gene (HTR2A) predict treatment response to venlafaxine XR in generalized anxiety disorder  
Falk Lohoff, MD  
University of Pennsylvania School of Medicine  
Philadelphia, PA, USA

11:45AM - 12:10PM  Meta-Analysis of antidepressant-associated suicidality in major depressive disorder  
Stephan Ripke, MD  
Massachusetts General Hospital  
Boston, MA, USA

12:10PM - 2:00PM  Lunch

PLENARY LECTURE: Bridging from rare alleles to common alleles and mechanism  

2:00PM - 3:00PM  David Goldman, MD  
National Institute of Alcohol Abuse and Alcoholism  
Rockville, MD, USA

3:00PM - 3:15PM  Presentation of 2012 PIP Travel Awards

3:15PM - 3:30PM  Break

SESSION III: PHARMACOGENETICS OF ADVERSE EVENTS  
Session chair: David Goldman, MD

3:30PM - 3:55PM  Antipsychotic induced weight gain and the important role of hypothalamus genes – update and novel findings in the NPY gene  
Daniel J. Müller, MD  
Centre for Addiction and Mental Health  
Toronto, ON, CA
3:55PM - 4:20PM  The influence of metabolic syndrome, physical activity, and genotype on catechol-o-methyl transferase promoter-region methylation in schizophrenia
Vicki Ellingrod, PharmD
University of Michigan
Ann Arbor, MI, USA

4:20PM - 4:45PM  Common variants near the melanocortin 4 receptor gene are associated with severe antipsychotic drug-induced weight gain
Anil K. Malhotra, MD
The Zucker Hillside Hospital
Glen Oaks, NY, USA

5:30PM - 7:30PM  Poster Session

SATURDAY, MARCH 31, 2012

9:00AM - 9:15AM  Welcome

SESSION IV: NOVEL APPROACHES TO DISSECTING HETEROGENEITY OF PSYCHIATRIC ILLNESS
Session chair: Steven Hamilton, MD, PhD

9:15AM - 9:40AM  Effects of genome-wide supported risk variants on brain connectivity across the adult lifespan
Aristotle Voineskos, MD
Centre for Addiction & Mental Health
Toronto, ON, CA

9:40AM - 10:05AM  Rare variant detection in schizophrenia
Todd Lencz, PhD
The Zucker Hillside Hospital
Glen Oaks, NY, USA

10:05AM - 10:30AM  Establishing biological sampling methodology for pharmacogenomics in young people
Katherine J. Aitchison, PhD
University of Alberta
Edmonton, AB, CA

10:30AM - 10:45AM  Break
SESSION V: PHARMACOGENETICS OF ANTI PSYCHOTIC DRUGS

Session chair: Katherine J. Aitchison, PhD

10:45AM - 11:10AM
The factor structure for the Positive and Negative Syndrome Scale (PANSS) in pharmacogenetics: 102T/C 5-HT2A polymorphism and response to risperidone
Alessandra Minelli, PhD
Brescia University School of Medicine
Brescia, Lombardy, IT

11:10AM - 11:35AM
Antipsychotic treatment and copy number variations – a pilot study
Celina Skjødt
Copenhagen University Hospital
Copenhagen, DK

11:35AM - 12:00PM
AKAP13, CACNA1, GRIK4 and GRIA1 genetic variations may be associated with haloperidol efficacy during acute treatment
Alessandro Serretti, MD, PhD
University of Bologna
Bologna, IT

12:00PM
Meeting adjourns